Recombinant Human CD30/TNFRSF8 Protein (C-His)

Measured by functional ELISA. Immobilized recombinant human CD30 binds brentuximab vedotin-derived reference antibody and soluble CD30L (TNFSF8) with EC50 values in the ng/mL range.

CD30 (TNFRSF8) is a member of the tumor necrosis factor receptor superfamily and a classic marker of lymphoid activation. Although low in most resting lymphocytes, CD30 is abundantly expressed on Hodgkin/Reed–Sternberg cells and anaplastic large-cell lymphoma, and its restricted expression profile made it the model antigen for antibody–drug conjugates: brentuximab vedotin pairs an anti-CD30 antibody with a microtubule-disrupting payload and has become standard therapy in Hodgkin lymphoma and ALCL. Soluble CD30 released by shedding serves as a disease-monitoring biomarker. Beyond ADCs, CD30-directed CAR-T constructs and bispecifics are under active development. Recombinant human CD30 extracellular domain provides the full ligand- and antibody-binding ectodomain needed for ADC screening, biosimilar QC and ligand–receptor studies.